Member Directory

Amplia Therapeutics

Member Contact: Prof. Chris Burns

Position: CEO and Managing Director

Industry: Biotech & Pharmaceuticals

Company Profile:

Amplia Therapeutics Limited (ASX: ATX) is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.

The first of these drugs, narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). Orphan Drug Designations for pancreatic cancer and IPF have been granted by the US FDA. The FDA has also cleared Amplia’s investigational new drug (IND) submission to allow for a clinical trial in pancreatic cancer in the US.

Amplia’s second pipeline drug, AMP886, inhibits FAK and also inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is currently being evaluated in preclinical models of cancer.

Home

News & opinion

Events

CLICK HERE TO SUBSCRIBE TO OUR NEWSLETTER

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.